Covered recipient · General Payments record
FORTUNE O ALABI
Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$45,672.69
224 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,770.00 | 25 |
| Consulting Fee | $7,498.00 | 6 |
| Food and Beverage | $5,331.97 | 187 |
| Education | $72.72 | 6 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,872.78 | 46 |
| AstraZeneca Pharmaceuticals LP | $9,812.35 | 41 |
| GlaxoSmithKline, LLC. | $6,613.75 | 33 |
| E.R. Squibb & Sons, L.L.C. | $5,633.01 | 3 |
| Insmed, Inc. | $3,345.79 | 11 |
| Mallinckrodt Hospital Products Inc. | $2,245.49 | 4 |
| Genentech USA, Inc. | $1,474.00 | 5 |
| GENZYME CORPORATION | $1,048.93 | 4 |
| United Therapeutics Corporation | $689.47 | 14 |
| Novartis Pharmaceuticals Corporation | $546.15 | 7 |
| Harmony Biosciences LLC | $333.11 | 10 |
| Philips Electronics North America Corporation | $251.82 | 15 |
| Grifols USA, LLC | $229.88 | 6 |
| Jazz Pharmaceuticals Inc. | $209.50 | 6 |
| Actelion Pharmaceuticals US, Inc. | $152.58 | 7 |
| Janssen Pharmaceuticals, Inc | $54.78 | 2 |
| Regeneron Healthcare Solutions, Inc. | $43.34 | 2 |
| Teva Pharmaceuticals USA, Inc. | $32.71 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $28.45 | 2 |
| Mylan Specialty L.P. | $15.62 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.51 | 1 |
| Sunovion Pharmaceuticals Inc. | $12.75 | 1 |
| Fisher & Paykel Healthcare Inc | $11.92 | 1 |
Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FORTUNE O ALABI
NPI 1124025309 · CMS profile ID 5179
Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine
KISSIMMEE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124025309?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124025309?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124025309?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 224 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124025309?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
224 matching records · $45,672.69 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 224.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $23.48 | 07/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735812591 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.55 | 07/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960809 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16.87 | 06/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960869 | CMS |
| Harmony Biosciences LLC | $125.00 | 06/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750463657 | CMS |
| AstraZeneca Pharmaceuticals LP | $79.97 | 06/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736206819 | CMS |
| GENZYME CORPORATION | $16.66 | 06/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744171959 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.43 | 06/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749527949 | CMS |
| Jazz Pharmaceuticals Inc. | $20.94 | 06/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744456927 | CMS |
| Novartis Pharmaceuticals Corporation | $124.96 | 06/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725498373 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.25 | 06/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960731 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.30 | 06/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960737 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3.88 | 06/17/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960859 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.65 | 06/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736367071 | CMS |
| Novartis Pharmaceuticals Corporation | $22.80 | 06/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725498411 | CMS |
| United Therapeutics Corporation | $3.85 | 06/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752464097 | CMS |
| GlaxoSmithKline, LLC. | $22.10 | 06/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738663673 | CMS |
| Jazz Pharmaceuticals Inc. | $16.77 | 06/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744463483 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.15 | 06/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736420009 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $7.57 | 06/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721008331 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.20 | 06/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736220841 | CMS |
| Genentech USA, Inc. | $18.90 | 05/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743013777 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10.88 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960741 | CMS |
| Harmony Biosciences LLC | $21.42 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750463645 | CMS |
| United Therapeutics Corporation | $13.37 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752463805 | CMS |
| United Therapeutics Corporation | $18.95 | 05/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752463777 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $0.80 | 05/26/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748513477 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.25 | 05/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736035305 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.10 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736046779 | CMS |
| GlaxoSmithKline, LLC. | $17.06 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738844803 | CMS |
| Philips Electronics North America Corporation | $16.45 | 05/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751366075 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.86 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960745 | CMS |
| Grifols USA, LLC | $20.05 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750406101 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.29 | 05/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735771781 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.51 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736128815 | CMS |
| GlaxoSmithKline, LLC. | $23.96 | 04/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738904899 | CMS |
| Mallinckrodt Hospital Products Inc. | $2,150.00 | 04/30/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751686935 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $505.00 | 04/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960840 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.32 | 04/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736129927 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $20.44 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960751 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.85 | 04/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735751591 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,808.00 | 04/21/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960879 | CMS |
| Grifols USA, LLC | $18.04 | 04/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750412281 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.38 | 04/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960757 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 04/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735981563 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.97 | 04/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720960761 | CMS |
| Harmony Biosciences LLC | $20.32 | 04/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750463643 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.79 | 04/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735981175 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,700.00 | 04/14/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736284833 | CMS |
| United Therapeutics Corporation | $17.90 | 04/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752463037 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.39 | 04/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735799221 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,081,614.25 | 273 |
| PY2024 | Principal investigator | $412,429.80 | 105 |
| PY2023 | Principal investigator | $292,193.10 | 31 |
| PY2022 | Recipient | $2,007.97 | 3 |
| PY2022 | Principal investigator | $476,702.71 | 107 |
| PY2021 | Principal investigator | $216,369.96 | 215 |
| PY2020 | Principal investigator | $23,505.46 | 4 |
| PY2019 | Principal investigator | $111,963.80 | 44 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
273 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $182.25 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184279978 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $641.25 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184279980 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184279982 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184279984 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 12/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184279986 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $239.83 | 12/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184277884 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $808.00 | 12/16/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797301 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184275271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184275273 |
| Principal investigator 1 | GENZYME CORPORATION | $2,398.00 | 12/08/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114172 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797309 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220797335 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,886.00 | 12/03/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797331 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 12/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 12/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672894 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266915 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266917 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266923 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266925 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266927 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $850.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266929 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 11/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,504.95 | 11/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 11/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 11/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672896 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,559.40 | 10/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797299 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,282.40 | 10/21/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797259 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $239.83 | 10/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251149 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $239.83 | 10/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251151 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,278.42 | 10/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS, LLC | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185540721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 10/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 10/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 10/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746112 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.47 | 09/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184244391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 09/24/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672882 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/24/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797257 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.00 | 09/23/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797297 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $98.24 | 09/23/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184239832 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.98 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184239834 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.98 | 09/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184239836 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,461.92 | 09/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237526 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,737.00 | 09/08/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797251 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.92 | 09/04/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797253 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 09/04/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 09/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 09/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 09/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $104.94 | 08/26/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 08/26/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.36 | 08/26/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.00 | 08/26/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672880 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 08/26/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 08/26/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.85 | 08/26/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746110 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,263.70 | 08/18/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797293 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,020.00 | 08/18/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797295 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 08/14/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797323 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,500.00 | 08/14/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797325 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797241 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $189.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797243 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,500.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797245 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797247 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $134.03 | 08/11/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797327 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $180.00 | 08/08/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797249 |
| Principal investigator 1 | GENZYME CORPORATION | $500.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 08/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 08/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 08/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746102 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,475.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797321 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $875.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797287 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,504.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797289 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,336.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 07/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672872 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.47 | 07/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184221114 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $47.25 | 07/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184221152 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166.25 | 07/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184221154 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $641.25 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $182.25 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220250 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.98 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220252 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 07/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220254 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,500.00 | 07/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184218023 |
| Principal investigator 1 | GENZYME CORPORATION | $1,366.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $239.83 | 07/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184214918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 07/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672860 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 07/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 07/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746100 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $125.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.98 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212035 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $25.98 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212037 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212049 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $475.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212081 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $239.83 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,381.59 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211803 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,424.63 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211825 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,483.00 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,989.24 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,106.28 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211931 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,500.00 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,500.00 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211973 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,200.50 | 06/24/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797283 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,500.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797271 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,950.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797273 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,848.22 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797275 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,050.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797277 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797279 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797281 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $871.00 | 06/11/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797307 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,500.00 | 06/09/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797305 |
| Principal investigator 1 | GENZYME CORPORATION | $21,482.00 | 06/09/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114145 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 06/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797303 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,500.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192125978 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,000.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192125984 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 06/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU | No dispute reported | 06/30/2026 | 1192130951 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,500.00 | 06/03/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220797333 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 06/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 06/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 06/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $82.92 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.72 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 05/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746134 |
| Principal investigator 1 | GENZYME CORPORATION | $1,888.00 | 05/19/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114155 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,000.00 | 05/17/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797285 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,500.70 | 05/09/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797267 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $172.34 | 05/09/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797319 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 05/02/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 05/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672846 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 05/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672848 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 05/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746096 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646696 |
| Principal investigator 1 | Insmed, Inc. | $119.73 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646698 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646700 |
| Principal investigator 1 | Insmed, Inc. | $124.28 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646702 |
| Principal investigator 1 | Insmed, Inc. | $147.94 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646704 |
| Principal investigator 1 | Insmed, Inc. | $134.68 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646706 |
| Principal investigator 1 | Insmed, Inc. | $152.88 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646708 |
| Principal investigator 1 | Insmed, Inc. | $135.33 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646710 |
| Principal investigator 1 | Insmed, Inc. | $152.88 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646712 |
| Principal investigator 1 | Insmed, Inc. | $22.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646714 |
| Principal investigator 1 | Insmed, Inc. | $22.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646716 |
| Principal investigator 1 | Insmed, Inc. | $22.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646718 |
| Principal investigator 1 | Insmed, Inc. | $4.16 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646720 |
| Principal investigator 1 | Insmed, Inc. | $4.16 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646722 |
| Principal investigator 1 | Insmed, Inc. | $9.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646724 |
| Principal investigator 1 | Insmed, Inc. | $22.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646726 |
| Principal investigator 1 | Insmed, Inc. | $22.75 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646728 |
| Principal investigator 1 | Insmed, Inc. | $4.16 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646730 |
| Principal investigator 1 | Insmed, Inc. | $135.33 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646732 |
| Principal investigator 1 | Insmed, Inc. | $126.23 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646734 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646736 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646738 |
| Principal investigator 1 | Insmed, Inc. | $141.18 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646740 |
| Principal investigator 1 | Insmed, Inc. | $137.02 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646742 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646744 |
| Principal investigator 1 | Insmed, Inc. | $119.73 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646746 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646748 |
| Principal investigator 1 | Insmed, Inc. | $124.28 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646750 |
| Principal investigator 1 | Insmed, Inc. | $124.28 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646752 |
| Principal investigator 1 | Insmed, Inc. | $147.94 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646754 |
| Principal investigator 1 | Insmed, Inc. | $122.07 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646756 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646758 |
| Principal investigator 1 | Insmed, Inc. | $134.68 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646760 |
| Principal investigator 1 | Insmed, Inc. | $152.88 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646762 |
| Principal investigator 1 | Insmed, Inc. | $135.33 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646764 |
| Principal investigator 1 | Insmed, Inc. | $126.23 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646766 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646768 |
| Principal investigator 1 | Insmed, Inc. | $21.71 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646770 |
| Principal investigator 1 | Insmed, Inc. | $141.18 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646772 |
| Principal investigator 1 | Insmed, Inc. | $137.02 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646774 |
| Principal investigator 1 | Insmed, Inc. | $141.83 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646776 |
| Principal investigator 1 | Insmed, Inc. | $1,000.00 | 04/28/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189646778 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.47 | 04/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) | No dispute reported | 06/30/2026 | 1184190237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 04/23/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 04/23/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672856 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $781.45 | 04/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184185689 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 04/22/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797317 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,127.60 | 04/09/2025 | Non-covered Recipient Entity AGA CLINICAL TRIALS | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185540719 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,926.60 | 04/09/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797315 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 04/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746094 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7.33 | 04/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 03/25/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 03/25/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.80 | 03/25/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 03/25/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672844 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,381.50 | 03/25/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672914 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672916 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672920 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672926 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 03/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746082 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 02/25/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 02/25/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.36 | 02/25/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 02/25/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746122 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.30 | 02/24/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746078 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,601.50 | 02/14/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797263 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/07/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797181 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,023.00 | 02/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192126028 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797193 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,100.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797195 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797197 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797199 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,259.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797201 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,018.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797205 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797207 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797209 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,100.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797211 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,811.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797213 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797215 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797217 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797219 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797221 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797223 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,918.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797225 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797227 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797229 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,583.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797231 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797233 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797235 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.00 | 02/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797237 |
| Principal investigator 1 | GENZYME CORPORATION | $1,366.00 | 02/04/2025 | Non-covered Recipient Entity Clinical Research Specialists Llc | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | No dispute reported | 06/30/2026 | 1226114134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672906 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672908 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672910 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672912 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672924 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 02/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746080 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797187 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,926.60 | 02/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797191 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $62,303.54 | 01/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS, LLC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185540723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.40 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.50 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220672836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672928 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672930 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.04 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672932 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672934 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672936 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672938 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672940 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.20 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672942 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 01/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 01/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 01/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746088 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.85 | 01/27/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746090 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,717.80 | 01/21/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797313 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $267,039.69 | 01/13/2025 | Non-covered Recipient Entity Clinical Research Specialists, Llc | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235998004 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,399.40 | 01/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH SPECIALISTS LLC | A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL | No dispute reported | 06/30/2026 | 1192130957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.48 | 01/09/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220746114 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $399,651.30 | 01/09/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists, Pa | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1235997317 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,389.90 | 01/07/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797183 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,435.80 | 01/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220797261 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $121.54 | 01/06/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220797311 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672898 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672900 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672902 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220672904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220672922 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.52 | 01/01/2025 | Non-covered Recipient Entity Florida Lung Asthma And Sleep Specialists | A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough | No dispute reported | 06/30/2026 | 1220746092 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Research Specialists LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220797185 |